SlideShare a Scribd company logo
1 of 35
Download to read offline
MohamedAbdulla M.D.
Prof. of ClinicalOncology
Cairo University
GSO – Raffles Hotel – Istanbul – 28/03/2015
 Amgen.
 Merck Serono.
 Roche.
 Jansen Cilag.
 Astellas.
 MSD.
 pfizer.
 Novartis.
 Cecum 14 %
 Ascending colon 10 %
 Transverse colon 12 %
 Descending colon 7 %
 Sigmoid colon 25 %
 Rectosigmoid junct 0.9 %
 Rectum 23 %
CA Cancer J Clin 2011;61:69–90.VC 2011American Cancer Society, Inc.
CA Cancer J Clin 2011;61:69–90. VC 2011 American Cancer Society, Inc.
50
Years
Risk Factors
• Genetic
• FH
• IBD
• Obesity
• Smoking
• Alcohol
• Aspirin
• NSAIDS
• Vegetables
• Physical
Activity
• Adequate
Folate
• Decreased
Caloric
Intake
Primary prevention of colorectal cancer. Gastroenterology 2010; 138:2029.
Better Life
Style
 Good prognostic
factors
 Old age
 Gender(F>M)
 Asymptomatic pts
 Polypoidal lesions
 Non circumferential
lesions
 Diploid
 Poor prognostic factors
 Obstruction
 Perforation
 Ulcerative lesion
 Adjacent structures
involvement
 Positive margins
 LVSI
 Signet cell carcinoma
 High CEA
 Tethered and fixed cancer
Tis T1 T2 T3 T4
Extension to an adjacent organ
Mucosa
Muscularis mucosae
Submucosa
Muscularis propria
Subserosa
Serosa
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through the muscularis propria into pericolorectal tissues
T4a Tumor penetrates to the surface of the visceral peritoneum
T4b Tumor directly invades or is adherent to other organs or structures
Rectal cancer: 2015  Updates
Stage 5-year Survival (%)
0,1 Tis,T1;No;Mo > 90
I T2;No;Mo 80-85
II T3-4;No;Mo 70-75
III T2;N1-3;Mo 70-75
III T3;N1-3;Mo 50-65
III T4;N1-2;Mo 25-45
IV M1 <3
 History: Polyps & Colorectal Malignancy.
 Physical Examination: DRE.
 Routine laboratory investigations (CEA)
 Rigid Segmoidoscopy.
 Full Colonoscopy.
 Biopsy.
Journal of Surgical Oncology 2009;99:65–70
 80-95% accurate in tumor staging
 70-75% accurate in mesorectal lymph node
staging
 Use is limited to lesion < 14 cm from anus, not
applicable for upper rectum, for stenosing
tumor
 Very useful in determining extension of
disease into anal canal (clinical important for
planning sphincter preserving surgery)
Figure. Endorectal ultrasound
of a T3 tumor of the rectum,
extension through the
muscularis propria, and into
perirectal fat.
 Part of routine workup.
 Useful in identifying enlarged pelvic and extra-pelvic lymph-
nodes and visceral metastasis.
 Limited utility in:
1. small primary cancer.
2. T – Stage assessment.
3. Peri-rectal lymph nodes assessment.
 Sensitivity 50-80%
 Specificity 30-80%
 Shows promise as the most sensitive study for
the detection of metastatic disease in the
liver and elsewhere.
 Sensitivity of 97% and specificity of 76% in
evaluating for recurrent colorectal cancer.
 MRI may be Superior For:
1. Large field of view.
2. Better for proximal & stenotic lesions.
3. Less operator and technique dependent.
4. Size & morphologic characterization of peri-rectal nodes.
 EUS may be Superior for:
1. More specific for muscularis propria invasion (T1 versusT2).
2. Significantly higher sensitivity forT3 disease.
High Resolution MRI & EUS  Complementary Information.
Bipat et al.Radiology. 2004;232(3):773.
MDTSurgery
Radiation
Therapy
Systemic
Therapy
Imaging
Psychologist
&
Rehabilitation
MDT & MultimodalityTreatment  Outcome is improving over time
Sauer et al. N Engl J Med 2004;351:1731-40.
 High LR following APR and AR: 20-50% (35%).
 Sphincter preservation.
 To live with a stoma.
 Infections and sexual dysfunction.
 The perfect scenario.
Clinical Colorectal Cancer,Vol. 4, No. 4, 233-240, 2004
 Removal of peri-rectal
tissues involving lateral &
circumferential margins of
mesorectal envelop.
Dis Colon Rectum. 2013 May;56(5):535-50.
Clinical Colorectal Cancer,Vol. 4, No. 4, 233-240, 2004
Clinical Colorectal Cancer,Vol. 4, No. 4, 233-240, 2004
 GITSG.
 NCCTG.
 NSABP R-01.
N Engl J Med 1986; 315:1294.
FJ Natl Cancer Inst 1988; 80:21.
N Engl J Med 1991; 324:709.
Adjuvant
Fluoroupyremidine
X 2 months
CRT – 6Weeks
Adjuvant
Fluoroupyremidine
X 2 months
N Engl J Med 2004;351:1731-40.
10 -Year RTh + S S P
LR 5% 11% < 0.0001
OAS 48% 49% 0.86
CCSD 17% 22% 0.04
Lancet Oncol 2011; 12: 575–82
Lancet Oncol 2011; 12: 575–82
1. T3 –T4 Lesions:The only definitive indication.
2. cT3N0: Should be treated (understaging).
3. Depth of Extramural Invasion:
 T3 lesions (>5 mm)  ++ LNs involvement  Higher
Cancer Specific Survival (54%Versus 85%).
 Selection of high riskT3 for treatment.
 Approved outside US.
4. T1 – 2 lesions with Positive Nodes.
5. Low situated lesions.
6. Invasion of mesorectal fascia.
Br J Cancer 2000; 82:1131.
Grade Regression Fibrosis
0 No All cells are viable
1 Minor < 25% fibrosis
2 Moderate 26 – 50%nFibrosis
3 Good >50%
4 Total NoViable Cells
Grade 10 – year DM P 10 –Year DFS P
0 - 1 39.6%
0.005
63%
0.0082 - 3 29.3% 73.6%
4 10.5 % 89.5%
J Clin Oncol 32:1554-1562. © 2014
British Journal of Surgery 2012; 99: 918–928
Can we Avoid Surgery?
The Cancer Journal •Volume 13, Number 3, May/June 2007
EQUIVALEN
T
Curr Opin Oncol 2012, 24:441–447
Curr Opin Oncol 2012, 24:441–447
Curr Opin Oncol 2012, 24:441–447
PolishTrial
Trans-Tasman
Radiation
OncologyGroup
• Local Recurrence.
• DFS
• Distant Recurrence
• OAS
• Severe LateToxicity
EQUIVALENT
J Clin Oncol 2012; 30:3827.
Br J Surg 2006; 93:1215
 Rectal cancer should be treated by MDT.
 Surgery is still the mainstay of treatment.
 Neoadjuvant CRT is more appealing than
postoperative schedule regarding outcome and
toxicity profile for patients with stage II & III rectal
cancer.
 Fluoroupyremidine therapy is still the backbone of
any regimen and can be substituted by the oral form.
 Long course radiation therapy is still preferred by
majority of treating groups.
 pCR is associated with significant improvement in
outcome.
 Still more research is awaited.
Rectal cancer: 2015  Updates

More Related Content

What's hot

Radiation for Colon and Rectal Cancer
Radiation for Colon and Rectal CancerRadiation for Colon and Rectal Cancer
Radiation for Colon and Rectal CancerRobert J Miller MD
 
Rectal cancer By Dr Efrem Ayalew Wossen
Rectal cancer By Dr Efrem Ayalew WossenRectal cancer By Dr Efrem Ayalew Wossen
Rectal cancer By Dr Efrem Ayalew WossenEfremAyalew
 
1. Anorectal Cancer Symptoms And Signs
1. Anorectal Cancer  Symptoms And Signs1. Anorectal Cancer  Symptoms And Signs
1. Anorectal Cancer Symptoms And Signsensteve
 
Colo rectal cancer management
Colo rectal cancer managementColo rectal cancer management
Colo rectal cancer managementBachar Raad
 
The best way to treat locally advanced rectal cancer
The best way to treat locally advanced rectal cancerThe best way to treat locally advanced rectal cancer
The best way to treat locally advanced rectal cancerMohamed Abdulla
 
Staging and Diagnostic approach of rectal cancer
 Staging and Diagnostic approach  of rectal cancer Staging and Diagnostic approach  of rectal cancer
Staging and Diagnostic approach of rectal cancerDr.Bhavin Vadodariya
 
CARCINOMA RECTUM MANAGEMENT
CARCINOMA RECTUM MANAGEMENTCARCINOMA RECTUM MANAGEMENT
CARCINOMA RECTUM MANAGEMENTNabeel Yahiya
 
Carcinoma rectum
Carcinoma   rectumCarcinoma   rectum
Carcinoma rectumbarun kumar
 
MRI Staging of Early Rectal Tumours- Gina Brown
MRI Staging of Early Rectal Tumours- Gina BrownMRI Staging of Early Rectal Tumours- Gina Brown
MRI Staging of Early Rectal Tumours- Gina Brownjimmystrein
 
Pre management of carcinoma urinary bladder
Pre management of carcinoma urinary bladderPre management of carcinoma urinary bladder
Pre management of carcinoma urinary bladdervrinda singla
 
Management of Rectal Cancer
Management of Rectal CancerManagement of Rectal Cancer
Management of Rectal CancerSubhash Thakur
 

What's hot (18)

Radiation for Colon and Rectal Cancer
Radiation for Colon and Rectal CancerRadiation for Colon and Rectal Cancer
Radiation for Colon and Rectal Cancer
 
Melanoma anal canal
Melanoma anal canalMelanoma anal canal
Melanoma anal canal
 
Rectal cancer By Dr Efrem Ayalew Wossen
Rectal cancer By Dr Efrem Ayalew WossenRectal cancer By Dr Efrem Ayalew Wossen
Rectal cancer By Dr Efrem Ayalew Wossen
 
1. Anorectal Cancer Symptoms And Signs
1. Anorectal Cancer  Symptoms And Signs1. Anorectal Cancer  Symptoms And Signs
1. Anorectal Cancer Symptoms And Signs
 
Colo rectal cancer management
Colo rectal cancer managementColo rectal cancer management
Colo rectal cancer management
 
The best way to treat locally advanced rectal cancer
The best way to treat locally advanced rectal cancerThe best way to treat locally advanced rectal cancer
The best way to treat locally advanced rectal cancer
 
Staging and Diagnostic approach of rectal cancer
 Staging and Diagnostic approach  of rectal cancer Staging and Diagnostic approach  of rectal cancer
Staging and Diagnostic approach of rectal cancer
 
CARCINOMA RECTUM MANAGEMENT
CARCINOMA RECTUM MANAGEMENTCARCINOMA RECTUM MANAGEMENT
CARCINOMA RECTUM MANAGEMENT
 
Ca Rectum Imaging
Ca Rectum ImagingCa Rectum Imaging
Ca Rectum Imaging
 
RECTAL CANCER adesiyakan
 RECTAL CANCER adesiyakan RECTAL CANCER adesiyakan
RECTAL CANCER adesiyakan
 
Rectal Cancer
Rectal CancerRectal Cancer
Rectal Cancer
 
Carcinoma rectum
Carcinoma   rectumCarcinoma   rectum
Carcinoma rectum
 
MRI Staging of Early Rectal Tumours- Gina Brown
MRI Staging of Early Rectal Tumours- Gina BrownMRI Staging of Early Rectal Tumours- Gina Brown
MRI Staging of Early Rectal Tumours- Gina Brown
 
Colon And Rectal Cancer
Colon And Rectal CancerColon And Rectal Cancer
Colon And Rectal Cancer
 
Anal canal
Anal canal Anal canal
Anal canal
 
Pre management of carcinoma urinary bladder
Pre management of carcinoma urinary bladderPre management of carcinoma urinary bladder
Pre management of carcinoma urinary bladder
 
Rectal Carcinoma
Rectal CarcinomaRectal Carcinoma
Rectal Carcinoma
 
Management of Rectal Cancer
Management of Rectal CancerManagement of Rectal Cancer
Management of Rectal Cancer
 

Viewers also liked

The Surgery for Rectal Cancer
The Surgery for Rectal CancerThe Surgery for Rectal Cancer
The Surgery for Rectal Cancerensteve
 
Surgery for Rectal Cancer
Surgery for Rectal CancerSurgery for Rectal Cancer
Surgery for Rectal Cancerensteve
 
Role of radiation in carcinoma rectum and colon
Role of radiation in carcinoma rectum and colon Role of radiation in carcinoma rectum and colon
Role of radiation in carcinoma rectum and colon Bharti Devnani
 
Neoadjuvant Therapy of Rectal Cancer: Pathologic Versus Clinical CR
Neoadjuvant Therapy of Rectal Cancer: Pathologic Versus Clinical CRNeoadjuvant Therapy of Rectal Cancer: Pathologic Versus Clinical CR
Neoadjuvant Therapy of Rectal Cancer: Pathologic Versus Clinical CRMohamed Abdulla
 
Rectal Cancer - Preop. Radiochemotherapy and Postop. Chemotherapy
Rectal Cancer - Preop. Radiochemotherapy and Postop. ChemotherapyRectal Cancer - Preop. Radiochemotherapy and Postop. Chemotherapy
Rectal Cancer - Preop. Radiochemotherapy and Postop. ChemotherapySociedadColoprocto
 
Cylindrical APR
Cylindrical APRCylindrical APR
Cylindrical APRensteve
 
CES 2016 02 - Colorectal cancer
CES 2016 02 - Colorectal cancerCES 2016 02 - Colorectal cancer
CES 2016 02 - Colorectal cancerMauricio Lema
 
Extralevator abdominoperineal excision
Extralevator abdominoperineal excisionExtralevator abdominoperineal excision
Extralevator abdominoperineal excisionYannick Nijs
 
Tumor board locally advanced rectal cancer
Tumor board locally advanced rectal cancerTumor board locally advanced rectal cancer
Tumor board locally advanced rectal cancerRanjita Pallavi
 
Laparoscopic Resection for Rectal Cancer
Laparoscopic Resection for Rectal CancerLaparoscopic Resection for Rectal Cancer
Laparoscopic Resection for Rectal Cancerensteve
 

Viewers also liked (15)

Carcinoma rectum (Rectal Cancer)
Carcinoma rectum (Rectal Cancer)Carcinoma rectum (Rectal Cancer)
Carcinoma rectum (Rectal Cancer)
 
The Surgery for Rectal Cancer
The Surgery for Rectal CancerThe Surgery for Rectal Cancer
The Surgery for Rectal Cancer
 
Surgery for Rectal Cancer
Surgery for Rectal CancerSurgery for Rectal Cancer
Surgery for Rectal Cancer
 
Role of radiation in carcinoma rectum and colon
Role of radiation in carcinoma rectum and colon Role of radiation in carcinoma rectum and colon
Role of radiation in carcinoma rectum and colon
 
Neoadjuvant Therapy of Rectal Cancer: Pathologic Versus Clinical CR
Neoadjuvant Therapy of Rectal Cancer: Pathologic Versus Clinical CRNeoadjuvant Therapy of Rectal Cancer: Pathologic Versus Clinical CR
Neoadjuvant Therapy of Rectal Cancer: Pathologic Versus Clinical CR
 
MCC 2011 - Slide 26
MCC 2011 - Slide 26MCC 2011 - Slide 26
MCC 2011 - Slide 26
 
Rectal Cancer - Preop. Radiochemotherapy and Postop. Chemotherapy
Rectal Cancer - Preop. Radiochemotherapy and Postop. ChemotherapyRectal Cancer - Preop. Radiochemotherapy and Postop. Chemotherapy
Rectal Cancer - Preop. Radiochemotherapy and Postop. Chemotherapy
 
Carcinoma oesophagus
Carcinoma oesophagusCarcinoma oesophagus
Carcinoma oesophagus
 
Anal canal cancer
Anal canal cancerAnal canal cancer
Anal canal cancer
 
Colorectal Cancer
Colorectal CancerColorectal Cancer
Colorectal Cancer
 
Cylindrical APR
Cylindrical APRCylindrical APR
Cylindrical APR
 
CES 2016 02 - Colorectal cancer
CES 2016 02 - Colorectal cancerCES 2016 02 - Colorectal cancer
CES 2016 02 - Colorectal cancer
 
Extralevator abdominoperineal excision
Extralevator abdominoperineal excisionExtralevator abdominoperineal excision
Extralevator abdominoperineal excision
 
Tumor board locally advanced rectal cancer
Tumor board locally advanced rectal cancerTumor board locally advanced rectal cancer
Tumor board locally advanced rectal cancer
 
Laparoscopic Resection for Rectal Cancer
Laparoscopic Resection for Rectal CancerLaparoscopic Resection for Rectal Cancer
Laparoscopic Resection for Rectal Cancer
 

Similar to Rectal cancer: 2015 Updates

Gastrointestinal stromal tumor (GIST) dr ridu kumar sharma
Gastrointestinal stromal tumor (GIST)  dr ridu kumar sharmaGastrointestinal stromal tumor (GIST)  dr ridu kumar sharma
Gastrointestinal stromal tumor (GIST) dr ridu kumar sharmaRidu Kumar Sharma
 
Carcinoma Colon And Management
Carcinoma Colon And ManagementCarcinoma Colon And Management
Carcinoma Colon And ManagementPGIMER, AIIMS
 
Ca esophagus by amos.pptx
Ca esophagus by amos.pptxCa esophagus by amos.pptx
Ca esophagus by amos.pptxAmos Brighton
 
Early ca esophagus
Early ca esophagusEarly ca esophagus
Early ca esophagusRajiv paul
 
Staging and management of ca stomach
Staging and management of ca stomachStaging and management of ca stomach
Staging and management of ca stomachdeepak2006
 
PROGNOSTIC AND PREDICTIVE FACTORS FOR METASTATIC CARCINOMA BREAST
PROGNOSTIC AND PREDICTIVE FACTORS FOR METASTATIC CARCINOMA BREASTPROGNOSTIC AND PREDICTIVE FACTORS FOR METASTATIC CARCINOMA BREAST
PROGNOSTIC AND PREDICTIVE FACTORS FOR METASTATIC CARCINOMA BREASTDrAnkitaPatel
 
Discuss the pathology of bladder cancers
Discuss the pathology of bladder cancersDiscuss the pathology of bladder cancers
Discuss the pathology of bladder cancersJim Badmus
 
1 Introduction To Oncology
1 Introduction To Oncology1 Introduction To Oncology
1 Introduction To OncologyMiami Dade
 
Cancer of the Colon
Cancer of the  ColonCancer of the  Colon
Cancer of the ColonNitin Jha
 
2.4 dr aleksandar celebic masterclass - dubrovnik 2011.
2.4 dr aleksandar celebic   masterclass - dubrovnik 2011.2.4 dr aleksandar celebic   masterclass - dubrovnik 2011.
2.4 dr aleksandar celebic masterclass - dubrovnik 2011.European School of Oncology
 
TD Vac.pptx
TD Vac.pptxTD Vac.pptx
TD Vac.pptxAnnaMag3
 
Liver cancer final3
Liver cancer final3Liver cancer final3
Liver cancer final3pryce27
 

Similar to Rectal cancer: 2015 Updates (20)

Gastrointestinal stromal tumor (GIST) dr ridu kumar sharma
Gastrointestinal stromal tumor (GIST)  dr ridu kumar sharmaGastrointestinal stromal tumor (GIST)  dr ridu kumar sharma
Gastrointestinal stromal tumor (GIST) dr ridu kumar sharma
 
Melanoma
MelanomaMelanoma
Melanoma
 
Ca esophagus
Ca esophagusCa esophagus
Ca esophagus
 
Carcinoma Colon And Management
Carcinoma Colon And ManagementCarcinoma Colon And Management
Carcinoma Colon And Management
 
Ca esophagus by amos.pptx
Ca esophagus by amos.pptxCa esophagus by amos.pptx
Ca esophagus by amos.pptx
 
Early ca esophagus
Early ca esophagusEarly ca esophagus
Early ca esophagus
 
Cancergastritis200810
Cancergastritis200810Cancergastritis200810
Cancergastritis200810
 
Lynch syndrome
Lynch syndromeLynch syndrome
Lynch syndrome
 
Staging and management of ca stomach
Staging and management of ca stomachStaging and management of ca stomach
Staging and management of ca stomach
 
Lung cancer
Lung cancerLung cancer
Lung cancer
 
PROGNOSTIC AND PREDICTIVE FACTORS FOR METASTATIC CARCINOMA BREAST
PROGNOSTIC AND PREDICTIVE FACTORS FOR METASTATIC CARCINOMA BREASTPROGNOSTIC AND PREDICTIVE FACTORS FOR METASTATIC CARCINOMA BREAST
PROGNOSTIC AND PREDICTIVE FACTORS FOR METASTATIC CARCINOMA BREAST
 
Discuss the pathology of bladder cancers
Discuss the pathology of bladder cancersDiscuss the pathology of bladder cancers
Discuss the pathology of bladder cancers
 
Thyroid presentation
Thyroid presentationThyroid presentation
Thyroid presentation
 
Gastric Carcinoma
Gastric CarcinomaGastric Carcinoma
Gastric Carcinoma
 
1 Introduction To Oncology
1 Introduction To Oncology1 Introduction To Oncology
1 Introduction To Oncology
 
Cancer of the Colon
Cancer of the  ColonCancer of the  Colon
Cancer of the Colon
 
BALKAN MCO 2011 - A. Celebic - Thyroid cancer
BALKAN MCO 2011 - A. Celebic - Thyroid cancer BALKAN MCO 2011 - A. Celebic - Thyroid cancer
BALKAN MCO 2011 - A. Celebic - Thyroid cancer
 
2.4 dr aleksandar celebic masterclass - dubrovnik 2011.
2.4 dr aleksandar celebic   masterclass - dubrovnik 2011.2.4 dr aleksandar celebic   masterclass - dubrovnik 2011.
2.4 dr aleksandar celebic masterclass - dubrovnik 2011.
 
TD Vac.pptx
TD Vac.pptxTD Vac.pptx
TD Vac.pptx
 
Liver cancer final3
Liver cancer final3Liver cancer final3
Liver cancer final3
 

More from Mohamed Abdulla

BTC - Durvalumab - AZ 2023.pptx
BTC - Durvalumab - AZ 2023.pptxBTC - Durvalumab - AZ 2023.pptx
BTC - Durvalumab - AZ 2023.pptxMohamed Abdulla
 
Ihof heterogenity &amp; personalized treatment crpc 2019
Ihof heterogenity &amp; personalized treatment crpc 2019Ihof heterogenity &amp; personalized treatment crpc 2019
Ihof heterogenity &amp; personalized treatment crpc 2019Mohamed Abdulla
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast CancerMohamed Abdulla
 
ovarian cancer - angiogenesis
ovarian cancer - angiogenesisovarian cancer - angiogenesis
ovarian cancer - angiogenesisMohamed Abdulla
 
Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Mohamed Abdulla
 
Ovarian Cancer; What is Behind the Scene
Ovarian Cancer; What is Behind the SceneOvarian Cancer; What is Behind the Scene
Ovarian Cancer; What is Behind the SceneMohamed Abdulla
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storyMohamed Abdulla
 
angiogenesis; a key player in all chapters of metastatic crc story2
angiogenesis; a key player in all chapters of metastatic crc story2angiogenesis; a key player in all chapters of metastatic crc story2
angiogenesis; a key player in all chapters of metastatic crc story2Mohamed Abdulla
 
Role of Apalutamide in management of M0 CRPC
Role of Apalutamide in management of M0 CRPCRole of Apalutamide in management of M0 CRPC
Role of Apalutamide in management of M0 CRPCMohamed Abdulla
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancerMohamed Abdulla
 
Basic principles of cancer immunotherapy
Basic principles of cancer immunotherapyBasic principles of cancer immunotherapy
Basic principles of cancer immunotherapyMohamed Abdulla
 
Astellas meeting, crpc- what we have in 2019
Astellas   meeting, crpc- what we have in 2019Astellas   meeting, crpc- what we have in 2019
Astellas meeting, crpc- what we have in 2019Mohamed Abdulla
 
Impact of 1ry tumor location on treatment guidelines of mCRC
Impact of 1ry tumor location on treatment guidelines of mCRCImpact of 1ry tumor location on treatment guidelines of mCRC
Impact of 1ry tumor location on treatment guidelines of mCRCMohamed Abdulla
 
Continuum of care of metastatic colorectal cancer
Continuum of care of metastatic colorectal cancerContinuum of care of metastatic colorectal cancer
Continuum of care of metastatic colorectal cancerMohamed Abdulla
 
Msd msi high solid tumors
Msd msi high solid tumorsMsd msi high solid tumors
Msd msi high solid tumorsMohamed Abdulla
 
Colon cancer sidedness 2018
Colon cancer sidedness 2018Colon cancer sidedness 2018
Colon cancer sidedness 2018Mohamed Abdulla
 
Prostate cancer the androgenic fortified dogma
Prostate cancer  the androgenic fortified dogmaProstate cancer  the androgenic fortified dogma
Prostate cancer the androgenic fortified dogmaMohamed Abdulla
 

More from Mohamed Abdulla (20)

mHSPC Feb 2023.pptx
mHSPC Feb 2023.pptxmHSPC Feb 2023.pptx
mHSPC Feb 2023.pptx
 
BTC - Durvalumab - AZ 2023.pptx
BTC - Durvalumab - AZ 2023.pptxBTC - Durvalumab - AZ 2023.pptx
BTC - Durvalumab - AZ 2023.pptx
 
Ihof heterogenity &amp; personalized treatment crpc 2019
Ihof heterogenity &amp; personalized treatment crpc 2019Ihof heterogenity &amp; personalized treatment crpc 2019
Ihof heterogenity &amp; personalized treatment crpc 2019
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast Cancer
 
ovarian cancer - angiogenesis
ovarian cancer - angiogenesisovarian cancer - angiogenesis
ovarian cancer - angiogenesis
 
Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019
 
Ovarian Cancer; What is Behind the Scene
Ovarian Cancer; What is Behind the SceneOvarian Cancer; What is Behind the Scene
Ovarian Cancer; What is Behind the Scene
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the story
 
angiogenesis; a key player in all chapters of metastatic crc story2
angiogenesis; a key player in all chapters of metastatic crc story2angiogenesis; a key player in all chapters of metastatic crc story2
angiogenesis; a key player in all chapters of metastatic crc story2
 
Role of Apalutamide in management of M0 CRPC
Role of Apalutamide in management of M0 CRPCRole of Apalutamide in management of M0 CRPC
Role of Apalutamide in management of M0 CRPC
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancer
 
Basic principles of cancer immunotherapy
Basic principles of cancer immunotherapyBasic principles of cancer immunotherapy
Basic principles of cancer immunotherapy
 
CRPC management
CRPC managementCRPC management
CRPC management
 
Astellas meeting, crpc- what we have in 2019
Astellas   meeting, crpc- what we have in 2019Astellas   meeting, crpc- what we have in 2019
Astellas meeting, crpc- what we have in 2019
 
Impact of 1ry tumor location on treatment guidelines of mCRC
Impact of 1ry tumor location on treatment guidelines of mCRCImpact of 1ry tumor location on treatment guidelines of mCRC
Impact of 1ry tumor location on treatment guidelines of mCRC
 
Rectal Cancer
Rectal Cancer Rectal Cancer
Rectal Cancer
 
Continuum of care of metastatic colorectal cancer
Continuum of care of metastatic colorectal cancerContinuum of care of metastatic colorectal cancer
Continuum of care of metastatic colorectal cancer
 
Msd msi high solid tumors
Msd msi high solid tumorsMsd msi high solid tumors
Msd msi high solid tumors
 
Colon cancer sidedness 2018
Colon cancer sidedness 2018Colon cancer sidedness 2018
Colon cancer sidedness 2018
 
Prostate cancer the androgenic fortified dogma
Prostate cancer  the androgenic fortified dogmaProstate cancer  the androgenic fortified dogma
Prostate cancer the androgenic fortified dogma
 

Recently uploaded

historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 

Recently uploaded (20)

historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 

Rectal cancer: 2015 Updates

  • 1. MohamedAbdulla M.D. Prof. of ClinicalOncology Cairo University GSO – Raffles Hotel – Istanbul – 28/03/2015
  • 2.  Amgen.  Merck Serono.  Roche.  Jansen Cilag.  Astellas.  MSD.  pfizer.  Novartis.
  • 3.  Cecum 14 %  Ascending colon 10 %  Transverse colon 12 %  Descending colon 7 %  Sigmoid colon 25 %  Rectosigmoid junct 0.9 %  Rectum 23 % CA Cancer J Clin 2011;61:69–90.VC 2011American Cancer Society, Inc.
  • 4. CA Cancer J Clin 2011;61:69–90. VC 2011 American Cancer Society, Inc. 50 Years
  • 5. Risk Factors • Genetic • FH • IBD • Obesity • Smoking • Alcohol • Aspirin • NSAIDS • Vegetables • Physical Activity • Adequate Folate • Decreased Caloric Intake Primary prevention of colorectal cancer. Gastroenterology 2010; 138:2029. Better Life Style
  • 6.  Good prognostic factors  Old age  Gender(F>M)  Asymptomatic pts  Polypoidal lesions  Non circumferential lesions  Diploid  Poor prognostic factors  Obstruction  Perforation  Ulcerative lesion  Adjacent structures involvement  Positive margins  LVSI  Signet cell carcinoma  High CEA  Tethered and fixed cancer
  • 7. Tis T1 T2 T3 T4 Extension to an adjacent organ Mucosa Muscularis mucosae Submucosa Muscularis propria Subserosa Serosa TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ: intraepithelial or invasion of lamina propria T1 Tumor invades submucosa T2 Tumor invades muscularis propria T3 Tumor invades through the muscularis propria into pericolorectal tissues T4a Tumor penetrates to the surface of the visceral peritoneum T4b Tumor directly invades or is adherent to other organs or structures
  • 9. Stage 5-year Survival (%) 0,1 Tis,T1;No;Mo > 90 I T2;No;Mo 80-85 II T3-4;No;Mo 70-75 III T2;N1-3;Mo 70-75 III T3;N1-3;Mo 50-65 III T4;N1-2;Mo 25-45 IV M1 <3
  • 10.  History: Polyps & Colorectal Malignancy.  Physical Examination: DRE.  Routine laboratory investigations (CEA)  Rigid Segmoidoscopy.  Full Colonoscopy.  Biopsy. Journal of Surgical Oncology 2009;99:65–70
  • 11.  80-95% accurate in tumor staging  70-75% accurate in mesorectal lymph node staging  Use is limited to lesion < 14 cm from anus, not applicable for upper rectum, for stenosing tumor  Very useful in determining extension of disease into anal canal (clinical important for planning sphincter preserving surgery) Figure. Endorectal ultrasound of a T3 tumor of the rectum, extension through the muscularis propria, and into perirectal fat.
  • 12.  Part of routine workup.  Useful in identifying enlarged pelvic and extra-pelvic lymph- nodes and visceral metastasis.  Limited utility in: 1. small primary cancer. 2. T – Stage assessment. 3. Peri-rectal lymph nodes assessment.  Sensitivity 50-80%  Specificity 30-80%
  • 13.  Shows promise as the most sensitive study for the detection of metastatic disease in the liver and elsewhere.  Sensitivity of 97% and specificity of 76% in evaluating for recurrent colorectal cancer.
  • 14.  MRI may be Superior For: 1. Large field of view. 2. Better for proximal & stenotic lesions. 3. Less operator and technique dependent. 4. Size & morphologic characterization of peri-rectal nodes.  EUS may be Superior for: 1. More specific for muscularis propria invasion (T1 versusT2). 2. Significantly higher sensitivity forT3 disease. High Resolution MRI & EUS  Complementary Information. Bipat et al.Radiology. 2004;232(3):773.
  • 16. MDT & MultimodalityTreatment  Outcome is improving over time Sauer et al. N Engl J Med 2004;351:1731-40.
  • 17.  High LR following APR and AR: 20-50% (35%).  Sphincter preservation.  To live with a stoma.  Infections and sexual dysfunction.  The perfect scenario.
  • 18. Clinical Colorectal Cancer,Vol. 4, No. 4, 233-240, 2004
  • 19.  Removal of peri-rectal tissues involving lateral & circumferential margins of mesorectal envelop. Dis Colon Rectum. 2013 May;56(5):535-50.
  • 20. Clinical Colorectal Cancer,Vol. 4, No. 4, 233-240, 2004
  • 21. Clinical Colorectal Cancer,Vol. 4, No. 4, 233-240, 2004
  • 22.  GITSG.  NCCTG.  NSABP R-01. N Engl J Med 1986; 315:1294. FJ Natl Cancer Inst 1988; 80:21. N Engl J Med 1991; 324:709. Adjuvant Fluoroupyremidine X 2 months CRT – 6Weeks Adjuvant Fluoroupyremidine X 2 months
  • 23. N Engl J Med 2004;351:1731-40.
  • 24. 10 -Year RTh + S S P LR 5% 11% < 0.0001 OAS 48% 49% 0.86 CCSD 17% 22% 0.04 Lancet Oncol 2011; 12: 575–82
  • 25. Lancet Oncol 2011; 12: 575–82
  • 26. 1. T3 –T4 Lesions:The only definitive indication. 2. cT3N0: Should be treated (understaging). 3. Depth of Extramural Invasion:  T3 lesions (>5 mm)  ++ LNs involvement  Higher Cancer Specific Survival (54%Versus 85%).  Selection of high riskT3 for treatment.  Approved outside US. 4. T1 – 2 lesions with Positive Nodes. 5. Low situated lesions. 6. Invasion of mesorectal fascia. Br J Cancer 2000; 82:1131.
  • 27. Grade Regression Fibrosis 0 No All cells are viable 1 Minor < 25% fibrosis 2 Moderate 26 – 50%nFibrosis 3 Good >50% 4 Total NoViable Cells Grade 10 – year DM P 10 –Year DFS P 0 - 1 39.6% 0.005 63% 0.0082 - 3 29.3% 73.6% 4 10.5 % 89.5% J Clin Oncol 32:1554-1562. © 2014
  • 28. British Journal of Surgery 2012; 99: 918–928 Can we Avoid Surgery?
  • 29. The Cancer Journal •Volume 13, Number 3, May/June 2007 EQUIVALEN T
  • 30. Curr Opin Oncol 2012, 24:441–447
  • 31. Curr Opin Oncol 2012, 24:441–447
  • 32. Curr Opin Oncol 2012, 24:441–447
  • 33. PolishTrial Trans-Tasman Radiation OncologyGroup • Local Recurrence. • DFS • Distant Recurrence • OAS • Severe LateToxicity EQUIVALENT J Clin Oncol 2012; 30:3827. Br J Surg 2006; 93:1215
  • 34.  Rectal cancer should be treated by MDT.  Surgery is still the mainstay of treatment.  Neoadjuvant CRT is more appealing than postoperative schedule regarding outcome and toxicity profile for patients with stage II & III rectal cancer.  Fluoroupyremidine therapy is still the backbone of any regimen and can be substituted by the oral form.  Long course radiation therapy is still preferred by majority of treating groups.  pCR is associated with significant improvement in outcome.  Still more research is awaited.